Prof. Peer says , “We were able to organize the delivery system in such a way that we target to only 14.9% of the cells that were involved in the inflammatory condition of the disease, without adversely affecting the other, non-involved, cells, which are completely healthy. Through specific binding to the cell sub-population, while delivering the RNA payload we were able to improve all indices of inflammation, from the animal’s weight to pro-inflammatory cytokines. We compared our results with those of antibodies that are currently on the market for Crohn’s and colitis patients and found that our results were the same or better, without causing most of the side effects that accompany the introduction of antibodies into the entire cell population”.
https://www.sciencedaily.com/releases/2021/06/210629120442.htm